NEW YORK – Newomics and Bruker announced on Wednesday a comarketing agreement around mass spectrometry solutions for drug discovery.
Under the agreement, the companies will market Berkeley, California-based Newomics' microflow-nanospray electrospray ionization products with Billerica, Massachusetts-based Bruker's maxis II and timsTOF Pro 2 mass spectrometers.
Newomics' core technology is its multinozzle emitter array (MEA) device, which splits sample flow into multiple smaller streams to improve sample ionization and mass spec performance.
"This comarketing agreement is built upon close collaborations between our R&D teams over the last several years," Michael Greig, director, pharma/biopharma Americas at Bruker, said in a statement. "We look forward to working with Newomics to create workflows using MnESI products on Bruker mass spectrometers for biologics and native mass spec applications."
"Our M3 emitter is the first commercial multinozzle emitter for mass spectrometry," Daojing Wang, Newomics' founder and CEO, said in a statement. "The new MnESI source directly addresses several key pain points in mass spectrometry analysis of native proteins, protein complexes, and oligonucleotides, and opens up new opportunities for biopharmaceutical and clinical research and development."
The agreement follows a comarketing deal Newomics signed with Thermo Fisher Scientific last year.